AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00935168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% Hydroxy-ethyl starch (130/0.4)
Description: Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
Study NCT00935168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
Study NCT02365168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cod_Double Blind Placebo Controlled Food Challenge
Description: DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
Study NCT02365168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salmon_Double Blind Placebo Controlled Food Challenge
Description: DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
Study NCT02365168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mackerel_Double Blind Placebo Controlled Food Challenge
Description: DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
Study NCT02365168 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo_Double Blind Placebo Controlled Food Challenge
Description: DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
Study NCT01958801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supraclavicular block
Description: Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
Study NCT01958801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
Study NCT03607864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coral bone graft and xenograft
Description: ligible patients will be randomized in equal proportions between control group(immediate implant placement with grafting with xenograft) and study group (immediate implant placement with grafting with coral bone) Patients of both groups will be subjected to standard panoramic radiographs, cone beam ct .~Crestal bone level will measured by cone beam ct. Local anesthesia will be given to the patient. Only sulcular incision line with reflection is used A peritome will be used for a traumatic extraction of remaining roots. The extraction socket will be evaluated for absence of any fenestration or granulation tissues implant will be inserted in extraction socket bodily palatal with grafting with coral bone and xenograft The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 5/0 prolene sutures.
Study NCT04033835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentalization Based Treatment-Introductory
Description: Mentalization Based Treatment-Introductory
Study NCT04033835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual
Study NCT02778230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control
Description: Snacks (2 baked goods) without fiber fortification.
Study NCT02235532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foramen Herbal Aloe toothpaste
Description: use of aloe-vera toothpaste for 30 days in the test group.
Study NCT02235532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride toothpaste
Description: use of signal toothpaste once a day for 30 days in the control group.
Study NCT00992316 — intervention group
Intervention type: DRUG
Intervention: PF-04531083
Description: solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
Study NCT00699517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMBRABULIN (AVE8062)
Description: I.V. infusion followed by administration of cisplatin
Study NCT00699517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.V. infusion followed by administration of cisplatin
Study NCT00917449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: Oral L-arginine (3.2 gr bid)for 18 months
Study NCT00917449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo BID for 18 months
Study NCT02921971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR156597
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous
Study NCT02921971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous
Study NCT00326898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00326898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00326898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study NCT00326898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT00326898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00326898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00326898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT00326898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT02503904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Tumescent Antibiotic Delivery & IV Delivery
Description: Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.
Study NCT02503904 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Tumescent Infiltration
Description: Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump
Study NCT02503904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)
Study NCT02953535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magicbuvir
Description: 1 tablet contains 400 mg sofosbuvir
Study NCT02953535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi (fist dose)
Description: 1 tablet contains 400 mg sofosbuvir
Study NCT02953535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi (second dose)
Description: 1 tablet contains 400 mg sofosbuvir
Study NCT00493870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
Study NCT00493870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
Study NCT00493870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: • Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
Study NCT00493870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 15-30 minutes on Day 1.
Study NCT00493870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 15-30 minutes on Day 1.
Study NCT02211274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Everyday Competence Assessment and Planning for Community Transitions
Description: The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
Study NCT03294018 — intervention group
Intervention type: OTHER
Intervention: Recording heart rate changes
Description: Recording heart rate changes during planned sugammadex administration.
Study NCT02236455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Relaxation Technique
Description: Audio relaxation technique created by an Icelandic Registered Nurse.
Study NCT01666470 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
Study NCT04072380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-G3031
Description: SUVN-G3031 Tablets
Study NCT04072380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets
Study NCT02750826 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health Education Program
Study NCT02750826 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Weight Loss Intervention
Study NCT02236455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Music Intervention
Description: Audio recordings of non-lyrical relaxing music
Study NCT02236455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature Therapy without Music
Description: Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
Study NCT02236455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature Therapy with Music
Description: Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
Study NCT01002807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Single Dose
Study NCT01002807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin XR
Description: Tablets, Oral, 1000 mg, Single Dose
Study NCT01002807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Glucophage
Description: Tablets, Oral, 1000 mg, Single Dose
Study NCT01017393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT01017393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine free
Study NCT01726751 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimultion (SCS)
Description: Electric stimulation of the spinal cord
Study NCT01726751 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal cord nerve stimulation
Study NCT02346760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UB-621
Description: 100 mg/ml, subcutaneous injection
Study NCT01908647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT fMRI
Description: Real-time fMRI with neurofeedback.
Study NCT01908647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computer based attention training.
Study NCT01908647 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control RT fMRI
Description: Control condition for real-time fMRI.
Study NCT01908647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control RT fMRI
Description: Control condition for real-time fMRI.
Study NCT01908647 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Cognitive Training
Description: Computer-based games used as a control for the computer based cognitive training intervention.
Study NCT01908647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Cognitive Training
Description: Computer-based games used as a control for the computer based cognitive training intervention.
Study NCT03943212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Rate Reduction
Description: Hemodialysis blood flow rate will be reduced by 100 mL/min, or to a minimum of 300 mL/min, whichever is higher. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
Study NCT03943212 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No changes will be made to the dialysis prescription. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
Study NCT02618304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Meibomian gland dysfunction
Description: artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
Study NCT04634058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 antibody combined with CTLA-4 antibody
Description: After 4 cycles of PD-L1 monoclonal antibody combined with CTLA-4 monoclonal antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
Study NCT02615990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erigo Pro
Description: Verticalization table with two integrated robotic devices for leg movement and cyclic loading
Study NCT02615990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Patients receive standard physical therapy.
Study NCT04469478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey and interview
Description: Patients and caregivers will provide information via surveys and interviews regarding their experience viewing diagnostic imaging using conventional methods and using Virtual Reality
Study NCT02439125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl
Description: 2.5 mg b.i.d. orally for 3 weeks
Study NCT02439125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl
Description: 5.0 mg b.i.d. orally for 3 weeks
Study NCT02439125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl
Description: 7.5 mg b.i.d. orally for 3 weeks
Study NCT02439125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: b.i.d. orally for 3 weeks
Study NCT00526682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Irvingia/cissus combo
Study NCT01931358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Description: 1 mL intramuscular injection containing 10\^6 CCID50/dose
Study NCT01931358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
Study NCT01931358 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC-HIV Placebo
Description: 1 mL per injection
Study NCT01931358 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIDSVAX B/E Placebo
Description: 1 mL per injection
Study NCT00223496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
Study NCT00781456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 91-day Levonorgestrel Oral Contraceptive
Description: 91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
Study NCT00781456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily to match experimental arm
Study NCT00528762 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Focus group discussion about puberty and body image lasting 1 1/2 hours.
Study NCT00488982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 every 21 days
Study NCT00488982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and GM-CSF
Description: Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
Study NCT01414257 — intervention group
Intervention type: DRUG
Intervention: Methotrexate (MTX)
Description: Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
Study NCT01673321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.
Study NCT00933049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Oral amoxicillin (25mg/kg/dose)for 5 days
Study NCT00933049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole
Description: Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
Study NCT00933049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin placebo
Study NCT00933049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole placebo
Study NCT04434274 — intervention group
Intervention type: DRUG
Intervention: Micronized Purified Flavonoid Fraction
Description: Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
Study NCT03393273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: * Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21~* melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation~* Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21
Study NCT02499432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement
Description: Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
Study NCT00421668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: zinc
Study NCT00421668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: Vitamins C, E, B1, B2, niacin, B6, folate and B12
Study NCT00421668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00557219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenoldopam (Corlopam)
Description: continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
Study NCT00557219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
Study NCT00557219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketanserin (Sufrexal)
Description: continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
Study NCT01726348 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
Study NCT00424827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Fluorouracil with External Beam Radiation
Description: This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.